Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

İNCEL UYSAL P., YALÇIN B., ÖKTEM A.

DERI HASTALIKLARI VE FRENGI ARSIVI, vol.51, no.4, pp.124-128, 2017 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.4274/turkderm.65983
  • Journal Name: DERI HASTALIKLARI VE FRENGI ARSIVI
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.124-128
  • Keywords: Bullous pemphigoid, immunotherapy, omalizumab, SERUM-LEVELS, IGE, AUTOANTIBODIES, AUTOIMMUNITY, ASSOCIATION, MANAGEMENT, RISK
  • Ankara University Affiliated: Yes

Abstract

Background and Design: In the era of biological therapies, omalizumab (OMZ), a monoclonal antibody which inhibits IgE, has been postulated to be effective in the treatment of bullous pemphigoid (BP). We report our dinical experience with the use of OMZ in the treatment of BR